Fight against cancer : our therapeutic responses | Pierre Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma regains China rights to Nerlynx and amends deal with Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Accord entre Pierre Fabre et Puma Biotechnology
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Pierre Fabre engagements | NERLYNX
